| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The narcotic analgesic oxycodone and κ-opioid receptor agonist nalfurafine are extremely effective against morphine-resistant multiple sclerosis-related pain. The effect of these analgesics against the multiple sclerosis-related pain may be partially mediated through the activation of κ-opioid receptors. In addition, the reduced analgesic effect of morphine against the multiple sclerosis-related pain may be caused by the desensitization of μ-opioid receptors that is revealed by the activation of NMDA receptors. In fact, the morphine analgesia reduced against the multiple sclerosis-related pain recovers by a single injection of NMDA receptor antagonists.
|
